Loading…
Lobbying Spend
—
Filings
8
Firms Hired
1
Active Period
2019–2020
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · third_quarter · Firm: COVE STRATEGIES
S. 340 - CREATES Act of 2019, The Orphan Drug Act, Drug Pricing, Advancing American Kidney Initiative
Client expense: — · Firm income: $20,000
Matched citations: S. 340
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · second_quarter · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
Client expense: — · Firm income: $20,000
Matched citations: S.340
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2020 · first_quarter · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019, The Orphan Drug Act, Drug pricing, Advancing American Kidney Initiative
Client expense: — · Firm income: $20,000
Matched citations: S.340
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · fourth_quarter · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Client expense: — · Firm income: $20,000
Matched citations: S.340
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · third_quarter · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Client expense: — · Firm income: $20,000
Matched citations: S.340
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · second_quarter · Firm: COVE STRATEGIES
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
Client expense: — · Firm income: $20,000
Matched citations: S.340
Source: Senate LDA